Table 1 Baseline characteristics of the study participants
|  | Suspected CAD (n = 41) | No evidence of CAD (n = 29) | p-value |
|---|---|---|---|
Age (years) | 60 ± 5 | 58 ± 6 | 0.237 |
Male (n,%) | 19 (46.3) | 9 (31.0) | 0.149 |
Body-mass index (kg/m2) | 25.7 ± 3.3 | 26.4 ± 3.6 | 0.468 |
SBP (mmHg) | 131 ± 18 | 122 ± 17 | 0.066 |
DBP(mmHg) | 74 ± 10 | 71 ± 8 | 0.305 |
Diabetes duration (years) | 9.1 ± 7.1 | 8.7 ± 6.1 | 0.813 |
Hypertension (n,%) | 29 (70.7) | 19 (65.5) | 0.418 |
Dyslipidemia (n,%) | 18 (62.1) | 27 (65.9) | 0.47 |
Family history of CAD (n,%) | 25 (61.0) | 17 (58.6) | 0.519 |
Smoking Hx (n,%) | Â | Â | 0.064 |
Never smoker | 29 (70.7) | 25 (86.2) | Â |
Ex-smoker | 4 (9.8) | 3 (10.3) | Â |
Current smoker | 8 (19.5) | 1 (3.4) | Â |
FPG (mg/dL) | 132 ± 46 | 136 ± 41 | 0.718 |
PPG-2 hrs (mg/dL) | 219 ± 104 | 196 ± 90 | 0.331 |
HbA1c (%) | 7.49 ± 1.24 | 7.14 ± 1.19 | 0.398 |
GA (%) | 19.7 ± 6.8 | 18.4 ± 4.9 | 0.362 |
hsCRP (mg/dL) | 2.75 ± 5.39 | 1.83 ± 2.23 | 0.335 |
Total cholesterol (mg/dL) | 175 ± 50 | 166 ± 43 | 0.414 |
LDL cholesterol (mg/dL) | 100 ± 37 | 94 ± 39 | 0.585 |
HDL cholesterol (mg/dL) | 45 ± 11 | 46 ± 12 | 0.745 |
TG (mg/dL) | 130 ± 76 | 118 ± 44 | 0.41 |
Postprandial TG (mg/dL) | 124 ± 60 | 112 ± 43 | 0.352 |
HOMAIR | 5.25 ± 6.51 | 4.18 ± 3.10 | 0.364 |
Framingham risk score (FRS) | 7.3 ± 5.6 | 5.2 ± 6.3 | 0.18 |
CACS | 206 ± 342 | 3 ± 13 | 0.003 |
Chemerin (ng/mL) | 201.3 ± 82.3 | 193.1 ± 75.9 | 0.674 |
Omentin (ng/mL) | 104.4 ± 29.4 | 106.4 ± 23.5 | 0.767 |
YKL-40 (ng/mL) | 148.6 ± 82.3 | 96.7 ± 73.0 | 0.013 |
sCD26 (ng/mL) | 381.5 ± 399.4 | 332.0 ± 188.9 | 0.494 |
Insulin (%) | 12 (29.3) | 9 (31.0) | 0.54 |
Sulfonylurea (%) | 18 (43.9) | 14 (48.3) | 0.453 |
Metformin (%) | 29 (70.7) | 24 (82.8) | 0.192 |
Thiazolidinedione (%) | 12 (29.3) | 7 (24.1) | 0.423 |
ARB or ACE inhibitors (%) | 26 (63.4) | 12 (41.4) | 0.057 |
Calcium channer blockers (%) | 10 (24.4) | 6 (20.7) | 0.474 |
Beta blockers (%) | 5 (12.2) | 2 (6.9) | 0.381 |
Statins (%) | 22 (53.7) | 15 (51.7) | 0.533 |